Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 17/20 | 0.46 |
| ▸ | FABP3 | P05413 | 6/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.44 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.44 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.44 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.44 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3636760 | 0.71 | PRKAB2 (0.41) | FABP4FABP3FABP5PRKAB2PRKAG1 | |
| SCHEMBL28074539 | 0.70 | DYRK1A (0.44) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL22681646 | 0.68 | AXL (0.47) | FABP4FABP3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL3569291 | 0.68 | ALOX5 (0.41) | — | |
| SCHEMBL1701274 | 0.68 | AHR (0.48) | FABP4PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1701859 | 0.68 | AHR (0.48) | FABP4PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL3570866 | 0.67 | GRIA1 (0.42) | FABP4 | |
| SCHEMBL2850180 | 0.67 | FABP3 (0.49) | FABP4FABP3FABP5 | |
| SCHEMBL267355 | 0.67 | LMNA (0.53) | — | |
| SCHEMBL1701850 | 0.67 | MAP3K14 (0.46) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100179109-A1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| EP-2167609-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009096996-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
| WO-2008124575-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179109-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | FABP4 1708/4885FABP3 574/4885FABP5 2059/4885 |
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | FABP4 1625/4885FABP3 604/4885FABP5 1958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.